Jakavi offers new treatment option in myelofibrosis

Jakavi (ruxolitinib) is a selective inhibitor of JAK 1 and 2 for use in disease-related splenomegaly or symptoms in primary myelofibrosis or myelofibrosis due to polycythaemia vera or essential thrombocythaemia.

The starting dose of Jakavi is dependent on baseline platelet count


Ruxolitinib inhibits the Janus-associated kinases (JAK) 1 and 2, which mediate the signalling of molecules involved in haematopoiesis and immune function.1 In myelofibrosis, there is typically a dysfunction of the JAK pathway.


Ruxolitinib displayed efficacy in two double-blind studies in patients with intermediate-2 or high-risk myelofibrosis. The first (COMFORT-I) compared ruxolitinib with placebo and the second (COMFORT-II) used best available therapy (BAT) as the comparator treatment.2,3

Reduced spleen volume

In COMFORT-I (n=309), 41.9% of ruxolitinib patients achieved a ≥35% reduction in spleen volume at 24 weeks compared with 0.7% of placebo patients (p<0.001). This reduction was maintained for 48 weeks or more in 67% of those who responded. Ruxolitinib was also associated with a significant survival advantage compared with placebo (13 versus 24 deaths, hazard ratio 0.5; p=0.05).2

In COMFORT-II (n=219), 28% of patients who received ruxolitinib had a ≥35% reduction in spleen volume at 48 weeks compared with 0% of patients who received BAT (p<0.001).3 In addition, there was a 56% reduction in mean palpable spleen length at 48 weeks in the ruxolitinib group compared with a 4% increase in the BAT group. The most common therapies in the BAT group were hydroxycarbamide and glucocorticoids.3

Well tolerated

Ruxolitinib was associated with symptom improvement and was generally well tolerated, with anaemia and thrombocytopenia the most commonly reported adverse effects.2,3


1.    Jakavi Summary of Product Characteristics, August 2012
2.    Verstovsek S et al. N Engl J Med 2012; 366: 799-807.
3.    Harrison C et al. N Engl J Med 2012; 366: 787-98.

View Jakavi drug record

Further information: Novartis

Follow MIMS on Twitter

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

More from MIMS

Deleted products - live tracker

EXCLUSIVE TO SUBSCRIBERS See the latest products removed...

Drug shortages - live tracker

EXCLUSIVE TO SUBSCRIBERS Use our constantly updated...

Pregnant woman having an ultrasound scan with a female sonographer

Valproate prescribing: plan for new regulatory measures without delay, instructs MHRA

A National Patient Safety Alert (NatPSA) has been issued...

Products coming soon - live tracker

EXCLUSIVE TO SUBSCRIBERS Monitor forthcoming UK drug...